Compositions and methods comprising anti-nrp2 antibodies

Patent metadata

Field	Value
Publication number	US-2025074990-A1
Application number	US-202418765952-A
Country	US
Kind code	A1
Filing date	Jul 8, 2024
Priority date	Apr 6, 2018
Publication date	Mar 6, 2025
Grant date	—

Abstract

Provided are antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, for example, human histidyl-tRNA synthetase (HRS), and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

First claim

1 . A therapeutic composition, comprising at least one antibody or antigen-binding fragment thereof that specifically binds to a human neuropilin-2 (NRP2) polypeptide (anti-NRP2 antibody) at an epitope in the B2 or C domain of human NRP2.

2 - 34 . (canceled)

35 . The therapeutic composition of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (V H ) sequence that comprises complementary determining region V H CDR1, V H CDR2, and V H CDR3 sequences and a light chain variable region (V L ) sequence that comprises complementary determining region V L CDR1, V L CDR2, and V L CDR3 sequences, wherein:
the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 23-25, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 26-28, respectively, the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 29-31, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 32-34, respectively, the V H CDR, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 65-67, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 68-70, respectively, the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 71-73, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 74-76, respectively.

36 . The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgA (including subclasses IgA1 and IgA2), IgD, IgE, IgG (including subclasses IgG1, IgG2, IgG3, and IgG4), or IgM Fc domain, optionally a human Fc domain, or a hybrid and/or variant thereof.

37 . The therapeutic composition of claim 36 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG1 or IgG3 Fc domain.

38 . The therapeutic composition of claim 36 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG2 or IgG4 Fc domain.

39 . The therapeutic composition of claim 38 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG1 or IgG4 Fc domain, optionally selected from SEQ ID NOs: 116-118.

40 . The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof is a monoclonal antibody.

41 . The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof is a humanized antibody.

42 . The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof is an Fv fragment, a single chain Fv (scFv) polypeptide, an adnectin, an anticalin, an aptamer, an avimer, a camelid antibody, a designed ankyrin repeat protein (DARPin), a minibody, a nanobody, or a unibody.

43 . The therapeutic composition of claim 1 , wherein the composition has a purity of at least about 80%, 85%, 90%, 95%, 98%, or 99% on a protein basis with respect to the at least one antibody or antigen-binding fragment, and is substantially aggregate-free and substantially endotoxin-free.

44 . (canceled)

45 . The therapeutic composition of claim 1 , wherein the therapeutic composition is a sterile, injectable solution, optionally suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration.

46 . The therapeutic composition of claim 1 , further comprising at least one additional agent selected from one or more of a cancer immunotherapy agent, a chemotherapeutic agent, a hormonal therapeutic agent, and a kinase inhibitor.

47 - 64 . (canceled)

65 . A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutic composition of claim 1 , wherein the disease or condition is an NRP2-associated disease or condition.

66 . (canceled)

67 . The method of claim 65 , wherein the disease or condition is selected from one or more of cancer and diseases and pathways associated with cancer, including cancer cell growth, initiation, migration, adhesion, invasion, and/or metastasis; diseases associated with inflammation, autoimmunity, and related inflammatory diseases, including diseases associated with inappropriate immune cell activation or migration such as Graft versus host disease (GVHD); diseases associated with lymphatic development, lymphangiogenesis, and lymphatic damage, including, for example, edema, lymphedema, secondary lymphedema, inappropriate fat absorption and deposition, excess fat deposition, and vascular permeability; diseases associated with infections, including latent infections; diseases associated with allergic disorders/diseases, allergic responses, including, for example, chronic obstructive pulmonary disorder (COPD), neutrophilic asthma, antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis, systemic lupus erythematosus, rheumatoid arthritis, inflammasome-related diseases, and skin-related neutrophil-mediated diseases such as pyoderma gangrenosum; diseases associated with granulomatous inflammatory diseases, including sarcoidosis and granulomas; diseases associated with fibrosis including fibrotic diseases, fibrosis, endothelial to mesenchymal transition (EMT), and wound healing; diseases associated with inappropriate smooth muscle contractility, and inappropriate vascular smooth muscle cell migration and adhesion; diseases associated with inappropriate autophagy, phagocytosis, and efferocytosis; diseases associated with inappropriate migratory cell movement; diseases associated with neuronal diseases, peripheral nervous system remodeling, and pain perception; and diseases associated with bone development and bone remodeling.

68 - 141 . (canceled)

Assignees

• Atyr Pharma Inc

Inventors

• Burman Luke
• Chong Yee Ting (Esther)
• Geng Yanyan
• Greene Leslie Nangle
• Hamel Kristina
• King David
• Menefee Ann
• Rauch Kaitlyn
• Xu Zhiwen
• Zhai Liting

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/72

  Increased effector function due to an Fc-modification · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title